Protease inhibitor monotherapy in African setting results in viral load, but not CD4, failure in the short term
Anti-nausea drug has anti-HIV effect too
Fixed dose ARV for children: half-dose to limit nevirapine rash is safe in first 2 weeks
Maraviroc potentially of benefit for many patients with late HIV diagnosis
Good results seen with NRTI-sparing regimens of atazanavir plus newer drug classes
Once-daily extended-release nevirapine works as well as twice-daily formulation
Experimental integrase inhibitor GSK-572 shows continued promise
Rilpivirine (TMC278) matches efavirenz in phase 3 studies, with fewer side-effects
TBR-652 blocks both CCR5 and CCR2, inhibiting HIV replication and reducing inflammation
